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BACKGROUND The MARVEL (Micra Atrial TRacking Using a Ventric-
ular AccELerometer) 2 study assessed the efficacy of atrioventricular
(AV) synchronous pacing with a Micra leadless pacemaker. Average
atrioventricular synchrony (AVS) was 89.2%. Previously, low ampli-
tude of the Micra-sensed atrial signal (A4) was observed to be a fac-
tor of low AVS.
OBJECTIVE The purpose of this study was to identify predictors of
A4 amplitude and high AVS.
METHODS We analyzed 64 patients enrolled in MARVEL 2 who had
visible P waves on electrocardiogram for assessing A4 amplitude and
40 patients with third-degree AV block for assessing AVS at rest.
High AVS was defined as .90% correct atrial-triggered ventricular
pacing. The association between clinical factors and echocardio-
graphic parameters with A4 amplitude was investigated using a
multivariable model with lasso variable selection. Variables associ-
ated with A4 amplitude together with premature ventricular
contraction burden, sinus rate, and sinus rate variability (standard
deviation of successive differences of P-P intervals [SDSD]) were as-
sessed for association with AVS.
RESULTS In univariate analysis, low A4 amplitude was inversely
related to atrial function assessed by E/A ratio and eʹ/aʹ ratio,
and was directly related to atrial contraction excursion (ACE) and
atrial strain (Ɛa) on echocardiography (all P .05). The multivari-
able lasso regression model found coronary artery bypass graft his-
tory, E/A ratio, ACE, and Ɛa were associated with low A4 amplitude.
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E/A ratio and SDSD were multivariable predictors of high AVS, with
.90% probability if E/A ,0.94 and SDSD ,5 bpm.
CONCLUSION Clinical parameters and echocardiographic markers
of atrial function are associated with A4 signal amplitude. High
AVS can be predicted by E/A ratio ,0.94 and low sinus rate vari-
ability at rest.
KEYWORDS Atrioventricular block; Atrioventricular synchrony;
Leadless pacing; Micra transcatheter pacemaker; Predictors
(Heart Rhythm 2020;17:2037–2045) © 2020 The Heart Rhythm
Society. Published by Elsevier Inc. on behalf of Heart Rhythm
Society. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
In patients with normal sinus rhythm (NSR) and high-degree
atrioventricular (AV) block, AV synchronous pacing mode
improves stroke volume, cardiac output, and quality of life,
and reduces the incidence of pacemaker syndrome and atrial
fibrillation (AF). However, it does not reduce mortality or
occurrence of stroke.1–3 Therefore, pacing modes that
preserve atrioventricular synchrony (AVS) are
recommended as a class I indication in patients who have
high-degree AV block and NSR requiring permanent pacing,
with dual-chamber pacemakers as the first choice and single-
lead VDD pacing systems as an alternative.4 Leadless pace-
makers were designed to reduce complications associated
with transvenous pacemakers, particularly lead- and
pocket-related complications, which historically have been
reported to range as high as 2%–12%.5,6 Leadless pace-
makers have demonstrated a high safety and efficacy profile.7
However, first-generation leadless pacemakers deliver only
ventricular pacing (VVI[R] mode), which largely limits their
use to patients with bradycardia and chronic AF and those
considered to be at high risk for complications related to im-
plantation of a leaded pacemaker. Recently, second-
generation leadless pacemakers have expanded pacing
modes to include AV synchronous pacing.
The MARVEL (Micra Atrial TRacking Using a Ventricu-
lar AccELerometer) 1 and 2 studies demonstrated the feasi-
bility of delivering AV synchronous pacing using a
ventricular Micra leadless pacemaker (Medtronic, Inc, Min-
neapolis,MN,US).8,9 Specifically, theMARVEL2 algorithm
demonstrated a generally high proportion of AVS in patients
withAVblock, showing.95%of patients had.70%AVS at
rest and increased left ventricular stroke volume. Notably, the
optimal percentage of AVS required to maintain benefit while
minimizing pacemaker syndrome has not been determined.
Two key factors influence high AVS with mechanical
sensing–based VDD pacing: preoperative patient selection
and postoperative management. Patient selection may be
the more important of these 2 factors. The amplitude of the
sensed mechanical atrial signal (A4) by the Micra accelerom-
eter cannot be assessed before the implant procedure but is
fundamental to ensure a high AVS percentage. Therefore,
we sought to identify clinical predictors of A4 signal ampli-
tude and determinants of a high AVS percentage.
Methods
Study design
The MARVEL 2 study was a prospective, nonrandomized
multicenter clinical trial.9 The primary aim of the MARVEL
2 study was to confirm the ability of an enhanced downloaded
algorithm (MARVEL 2 algorithm) to provide AV synchro-
nous pacing by mechanically sensing atrial contraction via
the accelerometer signal from a ventricular Micra leadless
pacemaker. The primary efficacy objective was to demon-
strate the superiority of the MARVEL 2 algorithm to provide
AV synchronous pacing relative to VVI pacing in subjects
with persistent third-degree AV block and NSR at rest.
The protocol was approved by all local ethics committees
and national regulatory agencies at each participating institu-
tion. All patients provided written informed consent.
Patients and procedures
All patients who were enrolled in the MARVEL 2 study and
received the MARVEL 2 algorithm download were eligible
for inclusion in this analysis. These patients were aged
.18 years, had a history of AV block, and had previously un-
dergone or were undergoing implant with a Micra.
The MARVEL 2 study procedures and algorithm
(Supplemental Figure S1) have been previously described.9
In brief, custom software was temporarily downloaded into
the Micra. A specialized Holter monitor was placed during
study procedures to collect the electrocardiogram (ECG),
electrogram (EGM), accelerometer waveform, and device
markers. Performance was characterized with the patient at
rest in a supine or sitting position (approximately 20 mi-
nutes).
Echocardiographic analysis
Echocardiograms were collected during VVI at a lower rate
of 50 bpm. An echocardiography core laboratory (United
Heart and Vascular, St. Paul, MN) measured parameters
related to cardiac function in 2-, 3-, 4-, and 5-chamber and
parasternal short-axis views. The laboratory was blinded to
patient and study center. Previous studies have shown that
atrial contraction can be seen in the right ventricular (RV)
tricuspid annular plane systolic excursion view.10,11 To char-
acterize atrial function in this view, we defined a parameter—
atrial contraction excursion (ACE)—as the displacement dur-
ing atrial contraction (Supplemental Figure S2).
ECG analysis
P waves were identified on surface ECG/Holter monitor by a
technician blinded to the device and algorithm markers. An
individual cardiac cycle was considered synchronous if a
paced or sensed ventricular event occurred within 300 ms
following a P wave. Sinus rate variability was calculated
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by the standard deviation of successive differences of
P-P intervals (SDSD) method.12
In a subset of patients (n 5 19) at 1 center (University
Hospitals of Leuven, Leuven, Belgium), high-fidelity mea-
surements of P-wave amplitude and duration were made
from a 12-lead ECG using the MUSE Cardiology Informa-
tion System (GE Medical Systems, Menomonee Falls, WI).
These measurements were made by 2 observers who were
blinded to AVS.
Statistical analysis
All patients with visible P waves on surface ECG were
included in the analysis of A4 amplitude (n 5 64), whereas
only those with a predominant rhythm of persistent third-
degree AV block and NSR (n 5 40) were included in the
analysis of AVS percentage, as patients with intact AV con-
duction would have high AVS regardless of A4 sensing.
Based on previous reports using conventional VDD pacing
systems, we defined high/satisfactory AVS as .90%.13–16
Demographics, medical history, and other baseline
variables were compared among patients with .90% and
90%AVS using theWilcoxon rank-sum test for continuous
variables and the Fisher exact test for continuous variables.
A4 amplitude was compared among patients with .90%
and 90% AVS using the Student t test.
A 2-step modelling process was used to identify predictors
of high AVS percentage (Supplemental Figure S3). First, to
utilize the largest number of patients we identified predictors
of A4 amplitude. Next we included any multivariable predic-
tors of A4 amplitude together with measures of sinus rate, si-
nus rate variability, and premature ventricular complex
(PVC) burden to identify predictors of high AVS.
Baseline medical history (n5 16 variables), cardiovascu-
lar medication use (n5 7 variables), echocardiographic mea-
sures (n 5 26 variables), months since Micra implant, and
device location in the RV were tested for univariate associa-
tion with A4 amplitude using ordinary linear regression
(Supplemental Table S1). After univariate regression, 9 echo-
cardiographic variables were dropped from multivariable
consideration because they were constructs of more clinically
relevant variables (eg, left atrial ejection fraction was
included, whereas left atrial end-diastolic volume and left
atrial end-systolic volume were excluded). Due to the pres-
ence of missing data (primarily in echocardiographic param-
eters), 100 imputed datasets with complete data were created
using multivariate imputation by chained equations (MICE).
Due to the large number of candidate prognostic variables
(n 5 42) relative to the total sample size, lasso regression
was used to identify multivariable predictors of A4 amplitude
in each of the 100 imputed datasets. Lasso is a regression
technique that selects variables maximizing prediction accu-
racy while penalizing overfitting rather than performing var-
iable selection based on traditional measures of statistical
significance. Candidate variables selected by lasso in at least
50% of imputed datasets were incorporated in the final
model. The final model for A4 amplitude was fit to each of
the imputed datasets using linear regression, with the results
pooled across the repeated analyses using Rubin’s rules to ac-
count for the added variability due to the missing data.
In addition, the association between the absolute value of
P-wave amplitude and P-wave duration with A4 amplitude
was quantified using the Pearson correlation coefficient.
Variables included in the final A4 amplitude model
together with sinus rate, sinus rate variability (SDSD), and
PVC burden were assessed for their univariate association
with high AVS using univariate logistic regression. As
none of these variables had missing values, multivariable
analysis was performed on the original dataset. Multivariable
predictors of high AVS were determined using lasso logistic
regression, with the final model fit using ordinary logistic
regression. In-sample discrimination ability of the final
model was assessed by determining the area under the
receiver operating characteristic curve (AUROC).
Analysis was conducted in SASVersion 9.4 (SAS Institute,
Cary, NC) and R (R Core Team, 2017), utilizing the mice,17
glmnet,18 and ROCR19 packages to implement MICE, lasso
variable selection, and ROC analyses, respectively.
Results
Baseline characteristics
Overall, 75 patients were enrolled in the MARVEL 2 study
and received the software download. Mean age was 77.5 6
11.8 years (range 21–94 years), and 30 patients (40%) were
female (Table 1). Among the 75 patients, 40 (53%) had
persistent third-degree AV block with NSR, 18 (24%) had
1:1 AV conduction, 6 (8%) had varying AV conduction
and NSR, and 11 (15%) did not have visible P waves on
ECG due to either AF or flutter (n 5 8) or noise on the
ECG (n 5 3). The 11 patients with no visible P waves on
ECG were excluded from the analysis of A4 amplitude
because the lack of P waves prevented association of A4 sig-
nals with confirmed atrial activity. Patient characteristics by
analysis cohort are listed in Table 1.
Median AVS in the 40 patients with persistent third-degree
AV block and NSR was 94.3% (interquartile range [IQR]
81.1%–97.4%). Of these patients, 25 (62.5%) had AVS
.90% (median AVS 96.9%; IQR 95.3%–98.1%); the remain-
ing 15 patients had AVS 90% (median AVS 79.6%; IQR
77.3%–81.6%). Among the patients with AVS .90%, mean
A4 amplitude was higher than in patients with AVS 90%
(3.16 1.2 m/s2 vs 2.46 0.8 m/s2; P5 .030) (Figure 1). Over-
all, mean A4 amplitude was 2.8 6 1.1 m/s2.
Factors associated with A4 amplitude
Of the 51 candidate predictor variables, 18 had a univariate as-
sociation with A4 amplitude at the P ,.1 level (Table 2 and
Supplemental Table S1). Variables related to atrial function
were associated with A4 amplitude, such as E/A ratio, ACE,
eʹ/aʹ ratio, and atrial strain (all P .05). There was no signifi-
cant association between device location and A4 amplitude. In
addition, age, body mass index, and RV ejection fraction were
not associated with A4 amplitude. There was no difference in
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A4 amplitude among patients with third-degree AV block and
NSR vs patients with intrinsic conduction.
The lasso regression model selected coronary artery
bypass graft history, E/A ratio, ACE, and atrial strain for their
multivariable association with A4 amplitude (Table 2). The
final model for A4 amplitude accounted for 37.9% of the
variability in the observed A4 amplitude.
In the subset of patients with high-fidelity measurements of
P-wave amplitude and duration, the strongest association with
A4 amplitude was P-wave amplitude in lead aVR (r 5 0.52;
P 5 .023). There was no association between A4 amplitude
and P-wave duration (r 5 0.13; P 5 .61).
Factors associated with AVS
The 4 multivariable predictors of A4 amplitude, plus average
sinus rate, sinus rate variability (SDSD ,5 bpm vs SDSD
5 bpm), and PVC burden (,2% vs 2%), were tested for
their univariate and multivariable relationship with high
AVS (Table 3).
None of the 40 patients with persistent third-degree AV
block and NSR were missing data from the 7 candidate pre-
dictors. The lasso procedure identified SDSD and E/A ratio
as multivariable predictors of high AVS. E/A ratio was nega-
tively associated with high AVS (odds ratio 0.4 per 0.23-unit
increase; 95% confidence interval [CI] 0.16–1.01; P5 .051),
and SDSD,5 bpm was positively associated with high AVS
(odds ratio 16.6; 95% CI 2.4–112.5; P 5 .004). The final
model for high AVS discriminated well with AUROC of
0.89 (95% CI 0.75–0.98). The model predicts a.90% prob-
ability of high AVS if E/A ,0.94 and SDSD ,5 bpm and a
,10% probability of high AVS if either (1) E/A .2.0 and
SDSD ,5 bpm or (2) E/A .1.3 and SDSD 5 bpm





amplitude (n 5 64)
AVB 1 NSF AVS .90%
(n 5 25)
AVB 1 NSF AVS 90%
(n 5 15) P value*
Age (y) .26
Mean 6 SD 77.5 6 11.8 77.0 6 12.4 78.8 6 10.2 73.0 6 16.3
Median (IQR) 81.0 (72.0–85.0) 80.0 (71.5–84.0) 80.0 (75.0–84.0) 77.0 (67.0–84.0)
BMI .72
Mean 6 SD 26.2 6 5.7 26.8 6 6.0 25.9 6 3.4 29.3 6 9.2
Median (IQR) 25.4 (22.6–28.0) 25.6 (23.4–28.4) 26.1 (23.2–28.4) 25.3 (23.6–33.1)
Female 30 (40.0%) 29 (45.3%) 16 (64.0%) 6 (40.0%) .19
LV ejection fraction (%) .38
Mean 6 SD 53.5 6 3.8 53.8 6 3.9 54.3 6 3.4 53.5 6 3.3
Median (IQR) 54.0 (52.0–56.0) 55.0 (52.0–56.0) 55.0 (53.0–56.0) 53.5 (51.0–56.0)
RV ejection fraction (%) .62
Mean 6 SD 43.0 6 8.2 43.0 6 8.4 43.3 6 9.7 41.5 6 9.2
Median (IQR) 42.9 (37.3–47.5) 43.0 (36.8–48.2) 42.9 (36.5–51.8) 42.1 (34.5–47.5)
LA end-diastolic volume (mL) .12
Mean 6 SD 54.9 6 19.4 52.3 6 18.6 46.1 6 12.0 58.7 6 23.0
Median (IQR) 56.0 (39.0–68.0) 53.0 (35.0–65.0) 43.0 (36.0–58.0) 65.0 (29.0–80.0)
Comorbidities [n (%)]
Hypertension 2 (69.3) 4 (70.3) 17 (68.0) 11 (73.3) 1
Atrial fibrillation 14 (18.7) 7 (10.9) 0 (0.0) 3 (20.0) .046
Diabetes 13 (17.3) 13 (20.3) 3 (12.0) 3 (20.0) 1
Coronary artery disease 23 (30.7) 20 (31.3) (20.0) 3 (20.0) 1
CABG 9 (12.0) 8 (12.) 3 (12.0) 1 (6.7) 1
Valve surgery 18 (24.0) 14 (21.9) (20.0) 2 (13.3) .69
COPD 7 (9.3) (7.8) 2 (8.0) 2 (13.3) 1
Dialysis 3 (4.0) 3 (4.7) 1 (4.0) 0 (0.0) 1
Device location [n (%)] .20
RVOT 12 (16.0) 11 (17.2) 1 (4.0) 3 (20.0)
RV high-septum 11 (14.7) 10 (1.6) 6 (24.0) 1 (6.7)
RV mid-septum 26 (34.7) 21 (32.8) 7 (28.0) 4 (26.7)
RV low-septum 12 (16.0) 10 (1.6) (20.0) 3 (20.0)
RV apex 12 (16.0) 10 (1.6) 6 (24.0) 2 (13.3)
Other 2 (2.7) 2 (3.1) 0 (0.0) 2 (13.3)
Predominant rhythm [n (%)] N/A
Complete AV block with NSR 40 (3.3) 40 (62.) 2 (100.0) 1 (100.0)
Intact AV conduction 18 (24.0) 17 (26.6) 0 (0.0) 0 (0.0)
Other rhythm 1 (20.0) 7 (10.9) 0 (0.0) 0 (0.0)
Indeterminate rhythm 2 (2.7) 0 (0.0) 0 (0.0) 0 (0.0)
AV5 atrioventricular; AVB5 high-degree atrioventricular block; AVS5 atrioventricular synchrony; BMI5 body mass index; CABG5 coronary artery bypass
graft; COPD5 chronic obstructive pulmonary disease; IQR5 interquartile range; LA5 left atrium; LV5 left ventricle; NSF5 normal sinus function; RV5 right
ventricle; RVOT 5 right ventricular outflow tract.
*P value for comparison between AVB1 NSR patients with.90% AV synchrony vs AVB1 NSR with90% synchrony based on Wilcoxon rank-sum test for contin-
uous variables and Fisher exact test for categorical variables.
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(Figure 2A). The relationship between E/A ratio, SDSD, and
AVS percentage is shown in Figure 2B.
Discussion
The present study evaluated both the predictors of the A4
signal amplitude mechanically detected by the accelerometer
contained in the Micra leadless pacemaker and the determi-
nants of high AVS during VDD mode. Our findings based
on the MARVEL 2 population provide insight into the selec-
tion of patients who could benefit from a leadless device that
promotes AVS.
Quality of the A4 signal
Although it is possible to track a low-amplitude A4 signal
with the MARVEL 2 algorithm, patients who exhibited
high AVS (.90%) had a mean A4 signal amplitude higher
than that of patients with a lower AVS (90%) (Figure 1).
In multivariable analysis, the amplitude of the A4 signal
correlated with the echocardiographic parameters E/A ratio,
ACE, and atrial strain. ACE and atrial strain both are markers
of atrial contraction strength.
Of interest, patient characteristics including age, bodymass
index, arterial blood pressure, and history of previous atrial
arrhythmia were not multivariable predictors of A4 amplitude.
Curiously, coronary artery bypass graft had a negative rela-
tionship with A4 amplitude. The reduction in A4 amplitude
may be related to severity of ischemic disease20 and to right
atrial cannulation during cardiopulmonary bypass surgery,
both factors potentially leading to a reduction in atrial contrac-
tion. Device position was not associated with A4 amplitude.
Therefore, no changes to the implant procedure of the Micra
are currently recommended to optimize A4 sensing.
In our study, a low A4 amplitude was associated with low
ACE and atrial strain, which are parameters of atrial function.
Whether AV synchronous pacing would be beneficial in pa-
tients with impaired atrial function is not clear. An increased
risk of stroke has been observed after the maze procedure in
patients in sinus rhythm with a low P-wave amplitude and
absence of left atrial mechanical activity.21 The lack of atrial
contractile activity may explain the absence of reported
benefit of DDD vs VVI pacing on mortality in patients
with NSR and high-degree AV block.1,2,22 Impairment of
atrial mechanical function over time also can lead to atrial
undersensing. Its clinical significance will need to be evalu-
ated in future clinical studies. Nevertheless, Marchandise
et al23 previously showed that atrial undersensing had no
clinical impact in patients with high-degree AV block treated
by a conventional VDD system.
In a small group of patients (n5 19), A4 signal amplitude
was correlated with the amplitude of the initial deflection of
the P wave measured in aVR derivation on 12-lead ECG. To
our knowledge, there is no clear evidence of a relationship be-
tween P-wave morphology and right atrial mechanical activity
in healthy atria. Nevertheless, a low P-wave amplitude (0.05
mV) in the septal anterior leads has been associated with
absence of left atrial mechanical contraction after modified
Maze procedures.21
Figure 1 A4 amplitude vs high atrioventricular (AV) synchrony status during rest in patients with persistent third-degree AV block and normal sinus rhythm
(n 5 40). Horizontal black lines on boxes are median values. Height of boxes corresponds to interquartile range. Points represent individual patient values.
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Table 2 Univariate and multivariable predictors of A4 amplitude during rest
Variable
type Variable Subjects Summary*
Univariate models Multivariable model
b (95% CI)† P value R2 b (95% CI)† P value
Baseline
medical history
Male 64 54.7% –0.57 (–1.25 to 0.10) .099 0.04




History of atrial arrhythmias 64 15.6% –0.81 (–1.73 to 0.11) .089 0.05
Previous CABG 64 12.5% –1.41 (–2.38 to –0.44) .006 0.12 –1.01 (–1.88 to –0.13) .025
Previous valve surgery 64 21.9% –0.80 (–1.60 to 0.00) .056 0.06




















































ACE5 atrial contraction excursion; CABG5 coronary artery bypass graft; CI5 confidence interval; LA5 left atrium; LV5 left ventricle; RV5 right ventricle;
TAPSE 5 tricuspid annular plane systolic excursion; TR 5 tricuspid regurgitation.
*Summary values are given as mean 6 SD, median, interquartile range, and range for continuous variables or percentage for categorical variables.
†Regression b values are standardized for continuous variables to represent an increase in 10% of the observed range.
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High AVS
No preimplant measurement of A4 signal amplitude is avail-
able to identify patients who may have high (or low) AVS.
Based on ECG and echocardiographic parameters, we
showed that low sinus rate variability (SDSD,5 bpm) com-
bined with E/A ratio,0.94 predicts high AVS (.90%) with
.90% probability. Furthermore, high sinus rate variability
and/or high E/A ratio can select patients unlikely to achieve
high AVS most of the time. Patient age and average sinus
rate had no influence on AVS.
Leadless pacemakers with a VDD pacing mode based on
mechanical atrial sensing are intended to treat patients with
high-degree AV block and NSR. Previously the cumulative
incidence of sinus node dysfunction at 5 years was shown
to be 2.6% in patients with no history of sinus dysfunction
and 4.6% in patients having a preimplant sinus rate .70
bpmwhen treated with single-lead VDD pacing.24 Therefore,
depending on a patient’s risk profile and the potential advan-
tage of the leadless pacing technology, dual-chamber pacing
systems should be preferred in the presence of sinus node
dysfunction and high-degree AV block.
Study limitations
Our study has several limitations related to the MARVEL 2
study design. First, AVS using a leadless pacing system
was evaluated at rest in a small number of patients for a short
duration (maximum 5 hours) during a single study visit. Sec-
ond, predictors of AVS were not assessed before Micra
implant, and chronic ventricular pacing may have altered
the echocardiographic parameters. Third, echocardiographic
analysis was performed in a core laboratory, whereas the
variability of echocardiographic measurements among indi-
vidual laboratories may be less consistent. Also, sinus vari-
ability is not frequently assessed, especially in patients with
third-degree AV block, and quantification of P-P intervals
in a clinical setting may be impractical. Therefore, the pro-
posed predictors for A4 amplitude and high AVS over time
should be validated in a larger population with longer
follow-up.
Conclusion
The amplitude of the sensed mechanical atrial signal (A4) by
the Micra accelerometer was related to atrial function as-
sessed by echocardiography. We were able to predict, with
high probability, high AVS.90% in the presence of E/A ra-
tio ,0.94 and low sinus rate variability at rest (assessed by
SDSD). These findings, if appropriately validated in a future
patient population, may be used to improve the selection of
patients for leadless VDD pacing systems.
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Table 3 Univariate and multivariable predictors of AVS during rest
Variable Subjects Summary*
Univariate models Multivariable model
Odds ratio (95% CI)† P value Odds ratio (95% CI)† P value
Previous CABG 40 10.0% 1.9 (0.2–20.2) .591
SDSD ,5 bpm 40 62.5% 14.4 (3.0–69.1) ,.001 16.6 (2.4–112.6) .004
PVC burden ,2% 40 92.5% 0.8 (0.1–9.9) .877
















PVC 5 premature ventricular complex; SDSD 5 standard deviation of successive P-P interval difference; other abbreviations as in Tables 1 and 2.
*Summary values are given as mean 6 SD, median, interquartile range, and range for continuous variables or percentage for categorical variables.
†Odd ratios are standardized for continuous variables to represent an increase in 10% of the observed range.
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